These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Mycophenolate mofetil eliminates the rationale for antilymphocyte induction therapy in nonhaploidentical living-donor kidney transplants. Shaffer D; Madras PN; Conway P; Davis C; Simpson MA; Monaco AP Transplant Proc; 1997; 29(1-2):342-3. PubMed ID: 9123031 [No Abstract] [Full Text] [Related]
8. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients. Fischer L; Sterneck M; Gahlemann CG; Malago M; Rogiers X; Broelsch CE Transplant Proc; 2000 Nov; 32(7):2125-7. PubMed ID: 11120098 [No Abstract] [Full Text] [Related]
9. Benefit of mycophenolate mofetil in patients with cyclosporine A-induced nephropathy after lung transplantation. Zuckermann A; Birsan T; Thaghavi S; Kupilik N; Deviatko E; Dekan G; Wolner E; Klepetko W Transplant Proc; 1999; 31(1-2):1160-1. PubMed ID: 10083518 [No Abstract] [Full Text] [Related]
10. Anti-T-cell-antibody prophylaxis in children: success with a novel combination strategy of mycophenolate mofetil and antithymocyte serum. Boucek MM; Pietra B; Sondheimer H; Luna M; Shaffer E; Hall P; Campbell D Transplant Proc; 1997 Dec; 29(8A):16S-20S. PubMed ID: 9414669 [No Abstract] [Full Text] [Related]
11. Mycophenolate mofetil, along with ATG and cyclosporine, significantly lowers the incidence of acute rejection episodes in renal transplant recipients. Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Iñigo V; Manresa JM; Masramón J Transplant Proc; 1999 Sep; 31(6):2259-60. PubMed ID: 10500567 [No Abstract] [Full Text] [Related]
12. Mycophenolate mofetil, ATG, and cyclosporine in the induction treatment of renal transplant recipients minimizes the incidence of acute rejection episodes. Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Marcas LI; Manresa JM; Masramón J Transplant Proc; 1998 Aug; 30(5):2226-7. PubMed ID: 9723449 [No Abstract] [Full Text] [Related]
13. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. The U.S. Mycophenolate Mofetil Study Group. Transplant Proc; 1997; 29(1-2):348-9. PubMed ID: 9123033 [No Abstract] [Full Text] [Related]
14. ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis. Kumar MS; Cahill K; Kumar AM; Panigrahi D; Seirka D; Singleton R; al-Abdullah IH; Laskow DA Transplant Proc; 1998 Jun; 30(4):1351-2. PubMed ID: 9636549 [No Abstract] [Full Text] [Related]
15. Histopathological findings in heart transplant patients under tacrolimus-mycophenolate mofetil versus cyclosporine microemulsion-azathioprine. Sgrosso JL; Ferrer J; Araujo G; Romeo L; Parisi C; Vázquez MC Transplant Proc; 2002 Feb; 34(1):115-6. PubMed ID: 11959214 [No Abstract] [Full Text] [Related]
16. Triple therapy with mycophenolate mofetil versus azathioprine. Muñiz ML; Amenabar J; Gómez-Ullate P; Urbizu J; Lampreabe I Transplant Proc; 1999; 31(1-2):1144-6. PubMed ID: 10083512 [No Abstract] [Full Text] [Related]
17. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation. Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415 [TBL] [Abstract][Full Text] [Related]
18. Optimization of the immunosuppressive protocol after lung transplantation. Reichenspurner H; Kur F; Treede H; Meiser BM; Deutsch O; Welz A; Vogelmeier C; Schwaiblmair M; Müller C; Fürst H; Briegel J; Reichart B Transplantation; 1999 Jul; 68(1):67-71. PubMed ID: 10428269 [TBL] [Abstract][Full Text] [Related]
19. Tacrolimus and azathioprine versus cyclosporine and mycophenolate mofetil after lung transplantation: a retrospective cohort study. Celik MR; Lederer DJ; Wilt J; Eser D; Bacchetta M; D'Ovidio F; Sonett JR; Arcasoy SM J Heart Lung Transplant; 2009 Jul; 28(7):697-703. PubMed ID: 19560698 [TBL] [Abstract][Full Text] [Related]
20. Role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients. Kuypers DR; Evenepoel P; Maes BD; Coosemans W; Pirenne J; Vanrenterghem YF Transplant Proc; 2002 Jun; 34(4):1164-70. PubMed ID: 12072305 [No Abstract] [Full Text] [Related] [Next] [New Search]